Serial measurement of FSTL1 beyond the 3 months may reveal whether its normalization is sustained, whether fluctuations correspond to OSA relapse or persistence, and if it carries prognostic value for long-term cardiovascular or metabolic outcomes. This evidence concerns the gene FSTL1 and obstructive sleep apnea syndrome.